Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 (2022)
- Authors:
- USP affiliated authors: SHINJO, SAMUEL KATSUYUKI - FM ; KUPA, LEONARD DE VINCI KANDA - FM ; SILVA, CLOVIS ARTUR ALMEIDA DA - FM ; BONFA, ELOISA SILVA DUTRA DE OLIVEIRA - FM
- Unidade: FM
- DOI: 10.1093/rheumatology/keab773
- Subjects: DOENÇAS AUTOIMUNES; VACINAS VIRAIS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Rheumatology
- ISSN: 1462-0324
- Volume/Número/Paginação/Ano: v. 61, n. 8, p. 3351-3361, 2022
- Este periódico é de assinatura
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: green
- Licença: other-oa
-
ABNT
SHINJO, Samuel Katsuyuki et al. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, v. 61, n. 8, p. 3351-3361, 2022Tradução . . Disponível em: https://doi.org/10.1093/rheumatology/keab773. Acesso em: 28 dez. 2025. -
APA
Shinjo, S. K., Souza, F. H. C. de, Borges, I. B. P., Santos, A. M. D., Miossi, R., Misse, R. G., et al. (2022). Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. Rheumatology, 61( 8), 3351-3361. doi:10.1093/rheumatology/keab773 -
NLM
Shinjo SK, Souza FHC de, Borges IBP, Santos AMD, Miossi R, Misse RG, Medeiros-Ribeiro AC, Kupa L de VK, Silva CAA da, Bonfa ESD de O. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 [Internet]. Rheumatology. 2022 ; 61( 8): 3351-3361.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1093/rheumatology/keab773 -
Vancouver
Shinjo SK, Souza FHC de, Borges IBP, Santos AMD, Miossi R, Misse RG, Medeiros-Ribeiro AC, Kupa L de VK, Silva CAA da, Bonfa ESD de O. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2 [Internet]. Rheumatology. 2022 ; 61( 8): 3351-3361.[citado 2025 dez. 28 ] Available from: https://doi.org/10.1093/rheumatology/keab773 - Reduced ovarian reserve in patients with adult polymyositis
- Thalidomide measurement in plasma and dried plasma spot by SPE combined with UHPLC-MS/MS for therapeutic drug monitoring
- SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy
- Subclinical Reduced Ovarian Reserve in Adult Polymiositis Patients
- Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis
- Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome
- Two-week methotrexate discontinuation in patients with rheumatoid arthritis vaccinated with inactivated SARS-CoV-2 vaccine: a randomised clinical trial
- Análise da função sexual de pacientes com dermatomiosite e polimiosite através de questionários autoaplicados: um estudo transversal
- Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases
- Myositis Specific-Autoantibodies: Predictors of Short-Term Good Outcome in Rituximab Treated-Refractory Idiopathic Inflammatory Myopathies
Informações sobre o DOI: 10.1093/rheumatology/keab773 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
